AtriCure's stock plummeted 5.58% during intraday trading on Wednesday, marking a significant decline for the medical device company.
The drop comes despite AtriCure reporting better-than-expected first-quarter results, with earnings narrowing to $0.00 per diluted share compared to an expected loss of $0.06, and revenue of $141.2 million exceeding estimates of $139.7 million. However, investors reacted negatively as the company maintained its full-year 2026 guidance of EPS between $0.00 and $0.04, which falls below the analyst consensus expectation of $0.06 per share.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.